MLchartDataset catalogue

Cablivi

Term · Oncology and biomedicine · MLC-T-ONC-001321

A drug used with plasma exchange and immunosuppressive therapy to treat acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare blood disorder in which blood clots form in small blood vessels throughout the body. Cablivi binds to a protein called VWF, which may help keep blood clots from forming. It is a type of nanobody (a tiny antibody). Also called caplacizumab.

Table 1. Record
IdentifierMLC-T-ONC-001321
FieldOncology and biomedicine
Synonymscaplacizumab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-001321",
  "term": "Cablivi",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with plasma exchange and immunosuppressive therapy to treat acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare blood disorder in which blood clots form in small blood vessels throughout the body. Cablivi binds to a protein called VWF, which may help keep blood clots from forming. It is a type of nanobody (a tiny antibody). Also called caplacizumab.",
  "synonyms": [
    "caplacizumab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/cablivi/"
}

Record 3,992 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.